NCT01789229 Establishment of a Tumor Bank for Tissue Samples
| NCT ID | NCT01789229 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Medical University of Vienna |
| Condition | Ovarian Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 10,000 participants |
| Start Date | 2003-09 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 10,000 participants in total. It began in 2003-09 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Establishment of a tumor bank, consisting of tissue samples of tumor patients (benign and malign tumors) and healthy people as controls. The tissue samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tissue tumor bank. This tumor bank for tissue samples, together with our tumorbank for blood samples (NCT01763125) combined constitute the entity "Tumorbank".
Eligibility Criteria
Inclusion Criteria: * Male/Female * Age 18 to 90 years max. * Just one current known malignant disease or just one current inflammatory disease Exclusion Criteria: * Inflammatory disease and malignant disease * multiple malignancies * multiple diseases * underage
Contact & Investigator
Robert Zeillinger, Prof.Dr.
PRINCIPAL INVESTIGATOR
Medical University of Vienna, Dptm. of Obstetrics & Gynaecology
Frequently Asked Questions
Who can join the NCT01789229 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ovarian Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT01789229 currently recruiting?
Yes, NCT01789229 is actively recruiting participants. Contact the research team at robert.zeillinger@meduniwien.ac.at for enrollment information.
Where is the NCT01789229 trial being conducted?
This trial is being conducted at Vienna, Austria, Leuven, Belgium, Berlin, Germany.
Who is sponsoring the NCT01789229 clinical trial?
NCT01789229 is sponsored by Medical University of Vienna. The principal investigator is Robert Zeillinger, Prof.Dr. at Medical University of Vienna, Dptm. of Obstetrics & Gynaecology. The trial plans to enroll 10,000 participants.